RxDoctor Payments Data

Eric Finkelstein, MD

Pain Medicine · Owings Mills, MDNPI 1821050931

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (49.8%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 50 manufacturers reported payments, led by Spinal Simplicity, LLC at 38.3% of the total. Reporting peaked in 2024 at $14,184 and has fallen 64.9% since, to $4,983 in 2025. Among pain medicine clinicians in MD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$37,278in general payments, 2019–2025

Across 589 payments — averaging $63.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Spinal Simplicity, LLC$14K
  • Saluda Medical Americas, Inc.$9K
  • Abbott$2K
  • MML US, Inc.$2K
  • Nevro Corp.$2K
  • Boston Scientific$1K
  • plus $6K from 44 others

What the payments were for

  • Consulting fees$18,56350%
  • Travel & lodging$5,43715%
  • Food & beverage$12,77834%
  • Education$5001%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$37,278 in reported general payments places this provider in the 95th percentile of 144 pain medicine providers in Maryland.

See all pain medicine providers in Maryland

Medicare billing

Part B allowed, 2024
$403,648
Medicare patients
478
Services billed
7,704

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BelbucaBuprenorphine Hcl15$14,343
Oxycodone Hcl543$9,905
Diclofenac Sodium66$7,990
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen216$6,271
ButransBuprenorphine14$6,233
Pregabalin213$5,382
Gabapentin294$5,025
Fentanyl18$4,682
Xtampza ErOxycodone Myristate11$3,892
Morphine Sulfate ErMorphine Sulfate93$3,324
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen156$2,983
Celecoxib113$2,817
Buprenorphine12$2,553
Baclofen165$2,051
Tizanidine Hcl166$1,963

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Belbuca, Xtampza Er$578$18,23526 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 144 pain medicine providers in Maryland.

Other pain medicine in Owings Mills

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →